SlideShare a Scribd company logo
1 of 44
TNM Classification of Malignant
Tumours - 8th edition
Changes between the 7th and 8th editions
“We unite the cancer community to reduce the global cancer
burden, to promote greater equity, and to integrate cancer
control into the world health and development agenda.”
December 2016
TNM-8
The TMN 8th edition is being published in December 2016.
The UICC TNM Project has published the 8th Edition of the TNM Classification
of Malignant Tumours that comes into effect on January 1, 2017. Since some
organizations may not be ready to adopt the new classification, we recommend
that the edition of the TNM classification be always included in data reporting
The following is a summary of the changes between the 7th and 8th
editions of TNM.
Major changes are listed and minor changes are identified.
TNM-8
New classifications:
• Oropharynx p16+ve
• Unknown primary cervical neck lymph nodes
• Skin head and neck cancers
• Thymus
• Neuroendocrine tumors: pancreas
• Osteosarcoma: Pelvic, Spine
• Soft tissue Sarcoma: Head and neck, Retroperitoneal, Thoracic and
Abdominal Viscera
Major modifications
• Head and Neck Nodes
• Nasopharynx
• Thyroid
• Esophagus
• Stomach
• Anal Cancer
• Liver
• Lung
• Prostate
• Ovary
Minor or no modifications
• Introduction
• Other Head and Neck carcinomas
• Hepatobiliary
• Small intestine, Colon and rectum
• Neuroendocrine
• Pleura
• Penis, Kidney, Ureter, Bladder, Urethra,
• Eye
• Malignant Lymphoma
New Structure
• Remove C factor from introduction
• Clarify ITC
• Add Prognostic Grid
• Essential TNM
• Paediatric Malignancies
ITC - UICC
• Isolated tumour cells (ITC) are single tumour cells or small clusters of
cells not more than 0.2 mm in greatest extent that can be detected by
routine H and E stains or immunohistochemistry. An additional criterion has
been proposed to include a cluster of fewer than 200 cells in a single
histological cross-section others have proposed that a cluster should have
20 cells or fewer; definitions of ITC may vary by tumour site.
• The exception is in Malignant Melanoma of the skin and Merkel Cell
Carcinoma, wherein ITC in a lymph node are classified as N1. These cases
should be analyzed separately.
Head and Neck Changes
• For all sites there are separate classifications for clinical and
pathological neck nodes
• There is a new classification for p16 positive oropharyngeal cancers.
Tumours that have p16 immunohistochemistry overexpression.
• The classification for nasopharyngeal cancers and thyroid cancers has
been modified
• The there is a new classification for squamous cell carcinoma of the skin
in the head and neck region
• There is a new classification for cervical nodal involvement with
unknown primary
Pathological
N1, N2a, N2b and N2c unchanged other than
specify without extranodal extension
• pN3a Metastasis in a lymph node more than 6
cm in greatest dimension without
extranodal extension
• pN3b Metastasis in a lymph node more than 3
cm in greatest dimension with extranodal
extension or, multiple ipsilateral, or any
contralateral or bilateral node(s) with
extranodal extension
Cervical Nodes – 8th edition
Clinical
N1, N2a, N2b and N2c unchanged other than
specify without extranodal extension
• N3a Metastasis in a lymph node more than 6
cm in greatest dimension without
extranodal extension
• N3b Metastasis in a single or multiple lymph
nodes with clinical extranodal extension*
* The presence of skin involvement or soft tissue invasion with
deep fixation/tethering to underlying muscle or adjacent structures
or clinical signs of nerve involvement is classified as clinical extra
nodal extension
Oropharynx p16 Positive tumours
Clinical and Pathological T categories
• T1 Tumour 2 cm or less in greatest dimension
• T2 Tumour more than 2 cm but not more than 4 cm
• T3 Tumour more than 4 cm in or extension to lingual surface of epiglottis
• T4 Tumour invades any of the following: larynx, deep/ extrinsic muscle of tongue
(genioglossus, hyoglossus, palatoglossus, and styloglossus), medial pterygoid, hard
palate, mandible*, lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, skull
base; or encases carotid artery
Oropharynx p16 Positive tumours
Clinical N categories
N0 No regional lymph node
metastasis
N1 Unilateral metastasis, in lymph
node(s), all 6 cm or less
N2 Contralateral or bilateral
metastasis in lymph node(s), all 6 cm
or less in greatest dimension
N3 Metastasis in lymph node(s)
greater than 6 cm in dimension
Pathological N categories
pN0 No regional lymph node
metastasis
pN1 Metastasis in 1 to 4 lymph
node(s)
pN2 Metastasis in 5 or more lymph
node(s)
Clinical
Stage I T1,T2 N0,1 M0
Stage II T1,T2 N2 M0
T3 N0,N1,N2 M0
Stage III T1-T4 N3 M0
T4 Any N M0
Stage IV Any T Any N M0
Pathological
Stage I T1,T2 N0,1 M0
Stage II T1,T2 N2 M0
T3 N0,N1
Stage III T3,T4 N2 M0
Stage IV Any T Any N M0
Oropharynx p16 Positive tumours
Nasopharynx
T categories
T1 Unchanged
T2 Tumour with extension to parapharyngeal space
and/or infiltration of the medial pterygoid, lateral
pterygoid, and/or prevertebral muscles
T3 Tumour invades bony structures of skull base
cervical vertebra, pterygoid structures, and/or
paranasal sinuses
T4 Tumour with intracranial extension and/or
involvement of cranial nerves, hypopharynx, orbit,
parotid gland and/or infiltration beyond the lateral
surface of the lateral pterygoid muscle
N Categories
N1 Unilateral metastasis, in cervical lymph node(s),
and/or unilateral or bilateral metastasis in retropharyn-
geal lymph nodes, 6 cm or less ,above the caudal
border of cricoid cartilage
N2 Bilateral metastasis in cervical lymph node(s), 6
cm or less above the caudal border of cricoid cartilage
N3 Metastasis in cervical lymph node(s) greater than 6
cm in dimension and/or extension below the caudal
border of cricoid cartilage
Nasopharynx
Cervical Node
Unknown Primary
If EBV positive stage as per nasopharyngeal
carcinomas
If p16 positive stage as per p16 positive
oropharynx carcinomas
If EBV and p16 negative clinical and
pathological node definitions are as
above
Stage III T0 N1 M0
Stage IVA T0 N2 M0
Stage IVB T0 N3 M0
Stage IVC T0 N1, N2, N3 M1
Thyroid Carcinoma
Papillary and Follicular
The definition of T3 has been revised for papillary and
follicular and medullary carcinomas
T3a Tumour more than 4 cm in greatest
dimension, limited to the thyroid
T3b Tumor of any size with gross extrathyroidal
extension invading only strap muscles
(sternohyoid, sternothyroid, or omohyoid
muscles)
The age for a poor prognosis has changed from 45 years
to 55 years
Stage < 55 years old
Stage I Any T Any N M0
Stage II Any T Any N M1
Stage >55 years old
Stage I T1a,T1b,T2 N0 M0
Stage II T3 N0 M0
T1, T2, T3 N1 M0
Stage III T4a Any N M0
Stage IVA T4b Any N M0
Stage IVB Any T Any N M1
TNM-8 Oesphagogastric Junction
Oesophagus and Gastric Carcinomas
• A tumour the epicenter of which is within 2 cm of the oesophagogastric
junction and also extends into the oesophagus is classified and staged
using the oesophageal scheme. Cancers involving the oesophagogastric
junction (OGJ) whose epicenter is within the proximal 2 cm of the cardia
(Siewert types I/II) are to be staged as oesophageal
• Cancers whose epicenter is more than 2 cm distal from the OGJ will be
staged using the Stomach Cancer TNM and Stage even if the OGJ is
involved.
Oesophagus
There are no changes in the definitions of the T, N and M categories.
Note there are pathological prognostic groups available for squamous cell carcinoma and
clinical and pathological prognostic groups available for adenocarcinoma
The AJCC also publish post preoperative therapy prognostic groups for adenocarcinoma and
squamous cell carcinoma
Oesophagus
Squamous Cell Carcinoma
Clinical Stage
Stage 0 Tis N0 M0
Stage I T1 N0, N1 M0
Stage II T2 N0, N1 M0
T3 N0 M0
Stage III T1,T2 N2 M0
T3 N1, N2 M0
Stage IVA T4a,T4b Any N M0
Stage IVA Any T N3 M0
Stage IVB Any T Any N M1
Pathological Stage
Stage 0 Tis N0 M0
Stage IA T1a N0 M0
Stage IB T1b N0 M0
T2 N0 M0
Stage II T3 N0 M0
T1 N1 M0
Stage IIIA T1 N2 M0
T2 N1 M0
Stage IIIB T2 N2 M0
T3 N1, N2 M0
T4a N0, N1 M0
Stage IVA T4a N2 M0
T4b Any N M0
Any T N3 M0
Stage IVB Any T Any N M1
Oesophagus Adenocarcinoma
Clinical Stage
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage IIA T1 N1 M0
IIB T2 N0 M0
Stage III T1 N2 M0
T2 N1, N2 M0
T3,T4a N0, N1, M0
Stage IVA T4b N0, N1 M0
Any T N2, N3 M0
Stage IVB Any T Any N M1
Pathological Stage
Stage 0 Tis N0 M0
Stage IA T1a N0 M0
Stage IB T1b N0 M0
Stage IIA T2 N0 M0
Stage IIB T1a,T1b N1 M0
Stage IIIA T1 N2 M0
T2 N1 M0
T3, T4a N0 M0
Stage IIIB T2 N2 M0
T3 N1, N2 M0
T4a N1 M0
Stage IVA T4a N2 M0
T4b Any N M0
Any T N3 M0
Stage IVB Any T Any N M1
Gastric Carcinoma
Adenocarcinoma
Clinical Stage
Stage I T1, T2, N0 M0
Stage IIA T1, T2, N1, N2, N3 M0
Stage IIB T3, T4a N0 M0
Stage III T3, T4a N1, N2, N3 M0
Stage IV T4b Any N M0
Stage IV Any T Any N M1
Pathological Stage
Stage 0 Tis N0 M0
Stage IA T1 N0 M0
Stage IB T1 N1 M0
T2 N0 M0
Stage IIA T1 N2 M0
T2 N1 M0
T3 N0 M0
Stage IIB T1 N3a M0
T2 N2 M0
T3 N1 M0
T4a N0 M0
Colon and Rectum
Definition of tumour deposit clarified
Tumour deposits (satellites) are discrete macroscopic or microscopic nodules of cancer in the
pericolorectal adipose tissue’s lymph drainage area of a primary carcinoma that are
discontinuous from the primary and without histological evidence of residual lymph node or
identifiable vascular or neural structures. If a vessel wall is identifiable on H&E, elastic or other
stains, it should be classified as venous invasion (V1/2) or lymphatic invasion (L1). Similarly, if
neural structures are identifiable, the lesion should be classified as perineural invasion (Pn1).
The presence of tumour deposits does not change the primary tumour T category, but changes
the node status (N) to N1c if all regional lymph nodes are negative on pathological examination
Colon and Rectum and Appendix
T and N categories Unchanged
M1 Distant metastasis
M1a Metastasis confined to one
organ (liver, lung, ovary,
non regional lymph node(s))
without peritoneal
metastases
M1b Metastasis in more than one
organ
M1c Metastasis to the
peritoneum with or without
other organ involvement
Stage Unchanged except for Stage IVA,
IVB, IVC as below
Stage IV Any T Any N M1
Stage IVA Any T Any N M1a
Stage IVB Any T Any N M1b
Stage IVC Any T Any N M1c
Appendix
Introduction of Tis (LAMN). Low-grade
appendiceal mucinous neoplasm confined
to the appendix
Changes to N and M categories and Stage
Anal Canal Carcinoma
Tumours of anal margin and perianal skin defined as
within 5cm of the anal margin are now classified with
carcinomas of the anal canal
T categories are unchanged
N0 No regional lymph node metastasis
N1 Metastasis in regional lymph node(s)
N1a Metastases in inguinal, mesorectal,
and/or internal iliac nodes
N1b Metastases in external iliac nodes
N1c Metastases in external iliac and in inguinal,
mesorectal and/or internal iliac nodes
M categories are unchanged
Stage
Stage I T1 N0 M0
Stage IIA T2 N0 M0
Stage IIB T3 N0 M0
Stage IIIA T1, T2 N1 M0
Stage IIIB T4 N0 M0
Stage IIIC T3, T4 N1 M0
Stage IV Any T Any N M1
Liver
T1a Solitary tumour less than or equal to 2 cm in
greatest dimension with or without vascular
invasion
T1b Solitary tumor more than 2 cm in greatest
dimension without vascular invasion
T2 Solitary tumour with vascular invasion more than 2
cm dimension or multiple tumours, none more than
5 cm in greatest dimension
T3 Multiple tumours any more than 5 cm in greatest
dimension
T4 Tumour(s) involving a major branch of the portal or
hepatic vein with direct invasion of adjacent organs
including the diaphragm), other than the gallbladder
or with perforation of visceral peritoneum
There are no changes in the definitions
of the N and M categories.
Stage
Stage I A T1a N0 M0
Stage I B T1b N0 M0
Stage II T2 N0 M0
Stage IIIA T3 N0 M0
Stage IIIB T4 N0 M0
Stage IVA Any T N1 M0
Stage IVB Any T Any N M1
Intrahepatic Bile Ducts
• Changes in definitions of T1 and T2 categories
• Changes in Stage
Gall Bladder
• Changes in definitions of T2 category and N
categories
• Change in Stage
Perihilar Bile Ducts No Changes
Distal Extrahepatic Bile Duct
• Changes in definitions of T1,T2,T3 categories
and N categories
• Changes in Stage
Ampulla of Vater
• Changes in definitions of T1,T2 and T3 categories and N
categories
• Changes in Stage
Well differentiated Neuroendocrine
Tumours of the Gastrointestinal Tract
• Pancreas added
• Minor changes in T categories.
• Changes in N category for Jejunum and Ileum
• Minor changes in Stage
Pancreas
T1 Tumour 2 cm or less
T1a Tumour 0.5 cm or less
T1b Tumour greater than 0.5 cm and
less than 1 cm
T1c Tumor greater than 1 cm but no
more than 2 cm
T2 Tumour more than 2 cm but no
more than 4 cm
T3 Tumour more than 4 cm in greatest
dimension
T4 Tumour involves coeliac axis, superior
mesenteric artery and/or common hepatic
artery
N1 Metastases in 1 to 3 nodes
N2 Metastases in 4 or more nodes
M category unchanged
Stage
Stage IA T1 N0 M0
Stage IB T2 N0 M0
Stage IIA T3 N0 M0
Stage IIB T1, T2, T3 N1 M0
Stage III T1, T2, T3 N2 M0
T4 Any N M0
Stage IV Any T Any N M1
Lung
T1 Tumour 3 cm or less
T1mi Minimally invasive adenocarcinoma
T1a Tumour 1 cm or less
T1b Tumour more than 1 cm but not more than 2 cm
T1c Tumour more than 2 cm but not more than 3 cm
T2 Tumour more than 3 cm but not more than 5 cm; or tumour with any of the
following features:
Involves main bronchus without involvement of the carina, or invades
visceral pleura or associated with atelectasis or obstructive
pneumonitis
T2a Tumour more than 3 cm but not more than 4 cm
T2b Tumour more than 4 cm but not more than 5 cm
Lung
T3 Tumour more than 5 cm but not more than 7 cm or directly invades: parietal pleura, chest wall,
phrenic nerve, or parietal pericardium; or separate tumour nodule(s) in the same lobe.
T4 Tumour more than 7 cm or of any size that invades any of the following: diaphragm,
mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral
body, carina; or separate tumour nodule(s) in a different ipsilateral lobe to the primary
N Category- No Change
M Category
M1a Separate tumour nodule(s) in a contralateral lobe; tumour with pleural or pericardial nodules or
malignant pleural or pericardial effusion
M1b Single extrathoracic metastasis in a single organ
M1c Multiple extrathoracic metastasis in a single or multiple organs
Lung
Stage IA T1 N0 M0
Stage IA1 T1mi,T1a N0 M0
Stage IA2 T1b N0 M0
Stage IA3 T1c N0 M0
Stage IB T2a N0 M0
Stage IIA T2b N0 M0
Stage IIB T1a-c, T2a,b N1 M0
T3 N0 M0
Stage IIIA T1a-c, T2a,b N2 M0
T3 N1
T4 N0,N1 M0
Stage IIIB T1a-c, T2a,b N3 M0
T3, T4 N2 M0
Stage IIIC T3, T4 N3 M0
Stage IV Any T Any N M1
Stage IVA Any T Any N M1a,b
Stage IVB Any T Any N M1c
Mesothelioma and Thymus
Mesothelioma
Minor change in T1 category
Changes in N category
Changes in Stage
Thymus
Please see details in
Nicholson AG, Detterbeck FC, Marino M et al. The
IASLC/ITMIG thymic epithelial tumors staging
project: proposals for the T component for the
forthcoming (8th) edition of the TNM classification of
malignant tumors. J Thorac Oncol 2014; 9: s73-
s80.
Bone and Soft Tissues Sarcoma
Bone
• No Changes for sarcomas of the
Appendicular Skeleton, Trunk, Skull and
Facial Bones
• New Classifications introduced for Spine
and Pelvic Bone Sarcomas
Soft Tissues sarcoma
New T categories for Extremity and
Superficial Trunk
T1 Tumour 5 cm or less
T2 Tumour more than 5 cm but no
more than 10 cm
T3 Tumour more than 10 cm but no
more than 15 cm
T4 Tumour more than 15 cm
New Classification for retroperitoneal sarcoma
(same as extremity) Head and Neck and also
Thoracic and Abdominal Viscera
Skin carcinomas
T categories
T1 < 2 cm
T2 > 2 to 4cm
T3 > 4 cm
T4a Tumor with gross cortical bone / marrow
invasion
T4b Tumor with skull base or axial skeleton
invasion including foraminal involvement
and/or vertebral foramen involvement to the
epidural space
N Categories for non head and neck
N1 Metastasis in a single lymph node
3 cm or less
N2 Metastasis in a single ipsilateral
lymph node, more than 3 cm but not
more than 6 cm or in multiple
ipsilateral nodes none more than 6 cm
N3 Metastasis in a lymph node more than
6 cm
Head and Neck Region
N categories as defined in slide 9
Skin carcinomas
Stage
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T3 N0 M0
T1, T2, T3 N1 M0
Stage IVA T1, T2, T3 N2, N3 M0
T4 Any N M0
Stage IVB Any T Any N M1
Malignant Melanoma & Merkel cell carcinoma
Cutaneous Melanoma
• pT1a and pT1b categories introduced
• pT1a < 0.8mm
• pT1b > 0.8mm -1mm
• M category
• M1a Skin, subcutaneous tissue or non regional
lymph nodes
• M1b Lung
• M1c Other non-central nervous system sites
• M1d Central nervous system
• M Category modified by elevated or non-elevated LDH
Stage Revised
Merkel cell
• Changes in cN and pN classification
and in Stage
Genitourinary Malignancies and Adrenal Cortex
Prostate
T4N0M0 is now stage III
WHO Grade should be used to record tumour
grade
Stage
Stage I T1, T2a N0 M0
Stage II T2b-2c N0 M0
Stage III T3,T4 N0 M0
Stage IV Any T N1 M0
Any T Any N M1
Penis
Changes in T category and pathological N
category
Kidney
N2 is eliminated
Genitourinary Malignancies and Adrenal Cortex
Urinary bladder
The M category is subdivided
M1a Non regional lymph nodes
M1b Other distant metastasis
Minor changes to Stage
Urethra
Changes to N category
N1 Metastasis in a single lymph node
N2 Metastasis in multiple lymph nodes
Adrenal Cortex
Change in Stage
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T1, T2 N1 M0
T3, T4 N0, N1 M0
Stage IV Any T Any N M1
Ovary – 8th ed TNM and Ovary, Fallopian Tube and
Primary Peritoneal Carcinoma based on FIGO 2014
FIGO has published a new classification for ovarian cancer*
This classification incorporates cancers of the fallopian tube and primary
peritoneal carcinomas
Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Jaime Prat; for the FIGO
Committee on Gynecologic Oncology. International Journal of Gynecology and Obstetrics 124 (2014)
1–5
Ovary, Fallopian Tube and Primary Peritoneum
T1 Limited to the ovaries I
Tla One ovary, (capsule intact) IA
or fallopian tube
Tlb Both ovaries, capsule intact IB
TIc1 Surgical Spill IC1
TIc2 Capsule ruptured before surgery or IC2
tumour on surface of ovary or tube
TIc3 Malignant cells in ascites or IC3
peritoneal washings
T2 Pelvic extension below pelvic brim
or primary peritoneal cancer II
T2a Uterus, tube(s), ovary (ies) IIA
T2b Other pelvic tissues IIB
T3 and/or Peritoneal metastasis beyond pelvis
N1 and/or regional lymph node metastasis III
T1/T2 N1 Retroperitonal nodes only IIIA1
T1/T2 N1a < 10mm IIIA1i
T1/T2 N1b > 10mm IIIA1ii
T3a N0/N1 Microscopic peritoneal metastasis
T3b N0/N1 Macroscopic peritoneal metastasis
< 2cm IIIB
T3c N0/N1 Peritoneal metastasis >2 cm IIIC
M1 Distant metastasis (excludes peritoneal)
IV
M1a Pleural effusion positive cytology IVB
M1b Parenchymal metastases IVB
Malignant Lymphoma
A recent consensus conference in Lugano suggested a more simplified system putting together
stage I and II as Limited Stage and stage III and IV as Advanced Stage lymphoma.
Limited Stage
• Stage I
• Stage II
• Bulky Stage II
Advanced Stage
• Stage III
• Stage IV
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and
response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin
Oncol. 2014;32: 3059-3068
Ophthalmic Tumours
Carcinoma of Conjunctiva
• Minor changes to definition of T1 and T2
categories
Malignant Melanoma of Conjunctiva
• Changes to the pathological T categories
Malignant Melanoma of Uvea
• Iris
• Minor changes to definition T2
category
Retinoblastoma
• Changes to definition of cT1 and cM
categories and pT and pM categories
Sarcoma of the Orbit
• Minor changes to definition of T1 and T2
categories
Carcinoma of Lacrimal Gland
• Changes to the T categories
Essential TNM
Information on anatomical extent of disease at presentation is often not available for cancer
registries in low and middle in-come countries either because of inability to perform necessary
investigations or because of lack of recording of information.
The UICC TNM Project has with the International Agency for Research in Cancer and the
National Cancer Institute developed “Essential TNM” that can be used to collect stage data
when complete information is not available.
When the T, N, and M categories have not been the cancer registrar can code the extent of
disease according to the Essential TNM scheme.
The schema for breast, colorectal cancer, prostate and cervix cancer published in the 8th edition
TNM Classification and are available on the website.
Paediatric Tumours
A consensus meeting held in 2014 recommended a tiered staging system
with more detailed systems for well-resourced cancer registries and less
detailed systems for registries with limited recourses and access
The recommendations for tier 1 and 2 follow are published the the 8th edition
TNM Classification of Malignant Tumours.
For some cancers recommendations are the same as described earlier for
adult patients.
UNION FOR INTERNATIONAL CANCER CONTROL
UNION INTERNATIONALE CONTRE LE CANCER
62 route de Frontenex, 1207 Geneva, Switzerland
T. +41 (0)22 809 1811 F. +41 (0)22 809 1810
www.uicc.org
Thank you

More Related Content

What's hot

NIH Presentation Nov 2016 Neuroendocrine Tumor Clinical Trials
NIH Presentation Nov 2016 Neuroendocrine Tumor Clinical TrialsNIH Presentation Nov 2016 Neuroendocrine Tumor Clinical Trials
NIH Presentation Nov 2016 Neuroendocrine Tumor Clinical TrialsCACSNETS
 
Locally Advanced Rectal Cancer
Locally Advanced Rectal CancerLocally Advanced Rectal Cancer
Locally Advanced Rectal CancerYamini Baviskar
 
Neck node management of unknown primary
Neck node management of unknown primaryNeck node management of unknown primary
Neck node management of unknown primaryDr Rekha Arya
 
Management of Carcinoma Larynx
Management of Carcinoma LarynxManagement of Carcinoma Larynx
Management of Carcinoma LarynxAnimesh Agrawal
 
Parathyroid tumors
Parathyroid tumorsParathyroid tumors
Parathyroid tumorsENT Resident
 
Differentiated thyroid carcinoma
Differentiated thyroid carcinomaDifferentiated thyroid carcinoma
Differentiated thyroid carcinomaARIJIT8891
 
Metastasis of unknown origin ppt final ppt
Metastasis of unknown origin ppt final pptMetastasis of unknown origin ppt final ppt
Metastasis of unknown origin ppt final pptDr.kavitha Palled
 
Cancer of unknown primary: Knowing the unknown
Cancer of unknown primary: Knowing the unknownCancer of unknown primary: Knowing the unknown
Cancer of unknown primary: Knowing the unknownMary Ondinee Manalo Igot
 
managment of neck nodes with occult primary
managment of neck nodes with occult primarymanagment of neck nodes with occult primary
managment of neck nodes with occult primaryBharti Devnani
 
Castrate Resistant Prostate Cancer
Castrate Resistant Prostate Cancer Castrate Resistant Prostate Cancer
Castrate Resistant Prostate Cancer Rohan Sharma
 
Metastatic neck disease
Metastatic neck diseaseMetastatic neck disease
Metastatic neck diseaseMamoon Ameen
 

What's hot (20)

NIH Presentation Nov 2016 Neuroendocrine Tumor Clinical Trials
NIH Presentation Nov 2016 Neuroendocrine Tumor Clinical TrialsNIH Presentation Nov 2016 Neuroendocrine Tumor Clinical Trials
NIH Presentation Nov 2016 Neuroendocrine Tumor Clinical Trials
 
Paranasal sinuses carcinoma
Paranasal sinuses carcinomaParanasal sinuses carcinoma
Paranasal sinuses carcinoma
 
Locally Advanced Rectal Cancer
Locally Advanced Rectal CancerLocally Advanced Rectal Cancer
Locally Advanced Rectal Cancer
 
Neck node management of unknown primary
Neck node management of unknown primaryNeck node management of unknown primary
Neck node management of unknown primary
 
Management of Carcinoma Larynx
Management of Carcinoma LarynxManagement of Carcinoma Larynx
Management of Carcinoma Larynx
 
CARCINOMA OF UNKNOWN PRIMARY NECK dr mnr
CARCINOMA OF UNKNOWN PRIMARY NECK  dr mnrCARCINOMA OF UNKNOWN PRIMARY NECK  dr mnr
CARCINOMA OF UNKNOWN PRIMARY NECK dr mnr
 
High Grade Glioma
High Grade GliomaHigh Grade Glioma
High Grade Glioma
 
Neck dissection
Neck dissectionNeck dissection
Neck dissection
 
Parathyroid tumors
Parathyroid tumorsParathyroid tumors
Parathyroid tumors
 
Neck dissection
Neck dissectionNeck dissection
Neck dissection
 
Salivary neoplasm
Salivary neoplasmSalivary neoplasm
Salivary neoplasm
 
Differentiated thyroid carcinoma
Differentiated thyroid carcinomaDifferentiated thyroid carcinoma
Differentiated thyroid carcinoma
 
Metastasis of unknown origin ppt final ppt
Metastasis of unknown origin ppt final pptMetastasis of unknown origin ppt final ppt
Metastasis of unknown origin ppt final ppt
 
Cancer of unknown primary: Knowing the unknown
Cancer of unknown primary: Knowing the unknownCancer of unknown primary: Knowing the unknown
Cancer of unknown primary: Knowing the unknown
 
managment of neck nodes with occult primary
managment of neck nodes with occult primarymanagment of neck nodes with occult primary
managment of neck nodes with occult primary
 
The principles of head and neck PET/CT
The principles of head and neck PET/CTThe principles of head and neck PET/CT
The principles of head and neck PET/CT
 
Sino nasal malignancies
Sino nasal malignanciesSino nasal malignancies
Sino nasal malignancies
 
Castrate Resistant Prostate Cancer
Castrate Resistant Prostate Cancer Castrate Resistant Prostate Cancer
Castrate Resistant Prostate Cancer
 
Metastatic neck disease
Metastatic neck diseaseMetastatic neck disease
Metastatic neck disease
 
Field cancerization
Field cancerizationField cancerization
Field cancerization
 

Similar to TNM8: Changes from TNM7

AJCC TNM staging of thyroid 8th edition ppt
AJCC TNM staging of thyroid 8th edition pptAJCC TNM staging of thyroid 8th edition ppt
AJCC TNM staging of thyroid 8th edition pptKanato Assumi
 
Management of ca larynx and hypopharynx
Management of ca larynx and hypopharynxManagement of ca larynx and hypopharynx
Management of ca larynx and hypopharynxVarshu Goel
 
That's cool a rossi la classificazione tnm cosa cambia 24 settembre 2010
That's cool a rossi la classificazione tnm cosa cambia 24 settembre 2010 That's cool a rossi la classificazione tnm cosa cambia 24 settembre 2010
That's cool a rossi la classificazione tnm cosa cambia 24 settembre 2010 coolesanum
 
Breast: Carcinoma in situ management
Breast: Carcinoma in situ management Breast: Carcinoma in situ management
Breast: Carcinoma in situ management Isha Jaiswal
 
Management of oral cavity cancer 23072018
Management of oral cavity cancer 23072018Management of oral cavity cancer 23072018
Management of oral cavity cancer 23072018Varshu Goel
 
bronchogenic carcinoma TNM-8 edition
bronchogenic carcinoma TNM-8 editionbronchogenic carcinoma TNM-8 edition
bronchogenic carcinoma TNM-8 edition1drrishisaini
 
Management of oropharyngeal tumors
Management of oropharyngeal tumorsManagement of oropharyngeal tumors
Management of oropharyngeal tumorsdeepak2006
 
Management of Oral Cavity Cancers
Management of Oral Cavity CancersManagement of Oral Cavity Cancers
Management of Oral Cavity CancersKUNALGUPTA294
 
Head and neck cancer staging
Head and neck cancer stagingHead and neck cancer staging
Head and neck cancer stagingDr Utkal Mishra
 
Update on Gastric AJCC 8th Ed.pdf
Update on Gastric AJCC 8th Ed.pdfUpdate on Gastric AJCC 8th Ed.pdf
Update on Gastric AJCC 8th Ed.pdfTemesgen Regasa
 
LARYNGEAL CANCER MANAGEMENT
LARYNGEAL CANCER MANAGEMENTLARYNGEAL CANCER MANAGEMENT
LARYNGEAL CANCER MANAGEMENTFaraz Badar
 
LOCALLY ADVANCED LUNG CANCER MANAGEMENT
LOCALLY ADVANCED LUNG CANCER MANAGEMENTLOCALLY ADVANCED LUNG CANCER MANAGEMENT
LOCALLY ADVANCED LUNG CANCER MANAGEMENTFaraz Badar
 

Similar to TNM8: Changes from TNM7 (20)

AJCC TNM staging of thyroid 8th edition ppt
AJCC TNM staging of thyroid 8th edition pptAJCC TNM staging of thyroid 8th edition ppt
AJCC TNM staging of thyroid 8th edition ppt
 
Thyroid Carcinoma.03
Thyroid Carcinoma.03Thyroid Carcinoma.03
Thyroid Carcinoma.03
 
Management of ca larynx and hypopharynx
Management of ca larynx and hypopharynxManagement of ca larynx and hypopharynx
Management of ca larynx and hypopharynx
 
That's cool a rossi la classificazione tnm cosa cambia 24 settembre 2010
That's cool a rossi la classificazione tnm cosa cambia 24 settembre 2010 That's cool a rossi la classificazione tnm cosa cambia 24 settembre 2010
That's cool a rossi la classificazione tnm cosa cambia 24 settembre 2010
 
Head And Neck Cancer
Head And Neck CancerHead And Neck Cancer
Head And Neck Cancer
 
Breast: Carcinoma in situ management
Breast: Carcinoma in situ management Breast: Carcinoma in situ management
Breast: Carcinoma in situ management
 
Testicular Cancer
Testicular Cancer Testicular Cancer
Testicular Cancer
 
Management of oral cavity cancer 23072018
Management of oral cavity cancer 23072018Management of oral cavity cancer 23072018
Management of oral cavity cancer 23072018
 
Esophageal carcinoma
Esophageal carcinomaEsophageal carcinoma
Esophageal carcinoma
 
bronchogenic carcinoma TNM-8 edition
bronchogenic carcinoma TNM-8 editionbronchogenic carcinoma TNM-8 edition
bronchogenic carcinoma TNM-8 edition
 
Colo rectal carcinoma
Colo rectal carcinomaColo rectal carcinoma
Colo rectal carcinoma
 
Management of oropharyngeal tumors
Management of oropharyngeal tumorsManagement of oropharyngeal tumors
Management of oropharyngeal tumors
 
Management of Oral Cavity Cancers
Management of Oral Cavity CancersManagement of Oral Cavity Cancers
Management of Oral Cavity Cancers
 
Head and neck cancer staging
Head and neck cancer stagingHead and neck cancer staging
Head and neck cancer staging
 
Metastatic Neck node of Unknown Primary
Metastatic Neck node of Unknown PrimaryMetastatic Neck node of Unknown Primary
Metastatic Neck node of Unknown Primary
 
Update on Gastric AJCC 8th Ed.pdf
Update on Gastric AJCC 8th Ed.pdfUpdate on Gastric AJCC 8th Ed.pdf
Update on Gastric AJCC 8th Ed.pdf
 
LARYNGEAL CANCER MANAGEMENT
LARYNGEAL CANCER MANAGEMENTLARYNGEAL CANCER MANAGEMENT
LARYNGEAL CANCER MANAGEMENT
 
Laryngeal malignancies
Laryngeal malignancies Laryngeal malignancies
Laryngeal malignancies
 
LOCALLY ADVANCED LUNG CANCER MANAGEMENT
LOCALLY ADVANCED LUNG CANCER MANAGEMENTLOCALLY ADVANCED LUNG CANCER MANAGEMENT
LOCALLY ADVANCED LUNG CANCER MANAGEMENT
 
Carcinoma lung
Carcinoma   lungCarcinoma   lung
Carcinoma lung
 

More from Mauricio Lema

Carga tumoral de cáncer renal - ConsultorSalud
Carga tumoral de cáncer renal - ConsultorSaludCarga tumoral de cáncer renal - ConsultorSalud
Carga tumoral de cáncer renal - ConsultorSaludMauricio Lema
 
Secuencia en cáncer gástrico metastásico (Versión 2)
Secuencia en cáncer gástrico metastásico (Versión 2)Secuencia en cáncer gástrico metastásico (Versión 2)
Secuencia en cáncer gástrico metastásico (Versión 2)Mauricio Lema
 
Secuencia en cáncer gástrico metastásico
Secuencia en cáncer gástrico metastásicoSecuencia en cáncer gástrico metastásico
Secuencia en cáncer gástrico metastásicoMauricio Lema
 
IO en SCLC (ampliado)
IO en SCLC (ampliado)IO en SCLC (ampliado)
IO en SCLC (ampliado)Mauricio Lema
 
CES202101 - Clase 15 parte 1 - Cáncer de cérvix
CES202101 - Clase 15 parte 1 - Cáncer de cérvix CES202101 - Clase 15 parte 1 - Cáncer de cérvix
CES202101 - Clase 15 parte 1 - Cáncer de cérvix Mauricio Lema
 
CES202101 - Clase 15 parte 2 - Cáncer de endometrio
CES202101 - Clase 15 parte 2 - Cáncer de endometrioCES202101 - Clase 15 parte 2 - Cáncer de endometrio
CES202101 - Clase 15 parte 2 - Cáncer de endometrioMauricio Lema
 
CES202101 - Clase 14 - Cáncer de ovario
CES202101 - Clase 14 - Cáncer de ovarioCES202101 - Clase 14 - Cáncer de ovario
CES202101 - Clase 14 - Cáncer de ovarioMauricio Lema
 
CES2021 - Clase 13 - Cáncer de pulmón (2/2)
CES2021 - Clase 13 - Cáncer de pulmón (2/2)CES2021 - Clase 13 - Cáncer de pulmón (2/2)
CES2021 - Clase 13 - Cáncer de pulmón (2/2)Mauricio Lema
 
CES202101 - Clase 12 - Cáncer de pulmón (1/2)
CES202101 - Clase 12 - Cáncer de pulmón (1/2) CES202101 - Clase 12 - Cáncer de pulmón (1/2)
CES202101 - Clase 12 - Cáncer de pulmón (1/2) Mauricio Lema
 
CES202101 - Clase 11 - Cáncer de mama (2/2) (José Julián Acevedo)
CES202101 - Clase 11 - Cáncer de mama (2/2) (José Julián Acevedo)CES202101 - Clase 11 - Cáncer de mama (2/2) (José Julián Acevedo)
CES202101 - Clase 11 - Cáncer de mama (2/2) (José Julián Acevedo)Mauricio Lema
 
CES202101 - Clase 10 - Cáncer de mama (1/2) (José Juilán Acevedo)
CES202101 - Clase 10 - Cáncer de mama (1/2) (José Juilán Acevedo)CES202101 - Clase 10 - Cáncer de mama (1/2) (José Juilán Acevedo)
CES202101 - Clase 10 - Cáncer de mama (1/2) (José Juilán Acevedo)Mauricio Lema
 
CES202101 - Clase 9 - Emergencias oncológicas - Parte 2/2
CES202101 - Clase 9 - Emergencias oncológicas - Parte 2/2CES202101 - Clase 9 - Emergencias oncológicas - Parte 2/2
CES202101 - Clase 9 - Emergencias oncológicas - Parte 2/2Mauricio Lema
 
CES202101 - Clase 8 - Neutropenia febril (Carlos Alberto Betancur Jiménez)
CES202101 - Clase 8 - Neutropenia febril (Carlos Alberto Betancur Jiménez)CES202101 - Clase 8 - Neutropenia febril (Carlos Alberto Betancur Jiménez)
CES202101 - Clase 8 - Neutropenia febril (Carlos Alberto Betancur Jiménez)Mauricio Lema
 
CES202101 - Clase 7 - Tamización para el cáncer (2/2)
CES202101 - Clase 7 - Tamización para el cáncer (2/2)CES202101 - Clase 7 - Tamización para el cáncer (2/2)
CES202101 - Clase 7 - Tamización para el cáncer (2/2)Mauricio Lema
 
CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)
CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)
CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)Mauricio Lema
 
CES202101 - Clase 5b - Cáncer de riñón (Daniel González)
CES202101 - Clase 5b - Cáncer de riñón (Daniel González)CES202101 - Clase 5b - Cáncer de riñón (Daniel González)
CES202101 - Clase 5b - Cáncer de riñón (Daniel González)Mauricio Lema
 

More from Mauricio Lema (20)

Carga tumoral de cáncer renal - ConsultorSalud
Carga tumoral de cáncer renal - ConsultorSaludCarga tumoral de cáncer renal - ConsultorSalud
Carga tumoral de cáncer renal - ConsultorSalud
 
NGS en oncología
NGS en oncologíaNGS en oncología
NGS en oncología
 
Secuencia en cáncer gástrico metastásico (Versión 2)
Secuencia en cáncer gástrico metastásico (Versión 2)Secuencia en cáncer gástrico metastásico (Versión 2)
Secuencia en cáncer gástrico metastásico (Versión 2)
 
Secuencia en cáncer gástrico metastásico
Secuencia en cáncer gástrico metastásicoSecuencia en cáncer gástrico metastásico
Secuencia en cáncer gástrico metastásico
 
IO en SCLC (ampliado)
IO en SCLC (ampliado)IO en SCLC (ampliado)
IO en SCLC (ampliado)
 
IO en SCLC
IO en SCLCIO en SCLC
IO en SCLC
 
IO en NSCLC
IO en NSCLCIO en NSCLC
IO en NSCLC
 
CES202101 - Clase 15 parte 1 - Cáncer de cérvix
CES202101 - Clase 15 parte 1 - Cáncer de cérvix CES202101 - Clase 15 parte 1 - Cáncer de cérvix
CES202101 - Clase 15 parte 1 - Cáncer de cérvix
 
CES202101 - Clase 15 parte 2 - Cáncer de endometrio
CES202101 - Clase 15 parte 2 - Cáncer de endometrioCES202101 - Clase 15 parte 2 - Cáncer de endometrio
CES202101 - Clase 15 parte 2 - Cáncer de endometrio
 
CES202101 - Clase 14 - Cáncer de ovario
CES202101 - Clase 14 - Cáncer de ovarioCES202101 - Clase 14 - Cáncer de ovario
CES202101 - Clase 14 - Cáncer de ovario
 
CES2021 - Clase 13 - Cáncer de pulmón (2/2)
CES2021 - Clase 13 - Cáncer de pulmón (2/2)CES2021 - Clase 13 - Cáncer de pulmón (2/2)
CES2021 - Clase 13 - Cáncer de pulmón (2/2)
 
CES202101 - Clase 12 - Cáncer de pulmón (1/2)
CES202101 - Clase 12 - Cáncer de pulmón (1/2) CES202101 - Clase 12 - Cáncer de pulmón (1/2)
CES202101 - Clase 12 - Cáncer de pulmón (1/2)
 
CES202101 - Clase 11 - Cáncer de mama (2/2) (José Julián Acevedo)
CES202101 - Clase 11 - Cáncer de mama (2/2) (José Julián Acevedo)CES202101 - Clase 11 - Cáncer de mama (2/2) (José Julián Acevedo)
CES202101 - Clase 11 - Cáncer de mama (2/2) (José Julián Acevedo)
 
CES202101 - Clase 10 - Cáncer de mama (1/2) (José Juilán Acevedo)
CES202101 - Clase 10 - Cáncer de mama (1/2) (José Juilán Acevedo)CES202101 - Clase 10 - Cáncer de mama (1/2) (José Juilán Acevedo)
CES202101 - Clase 10 - Cáncer de mama (1/2) (José Juilán Acevedo)
 
Slt
SltSlt
Slt
 
CES202101 - Clase 9 - Emergencias oncológicas - Parte 2/2
CES202101 - Clase 9 - Emergencias oncológicas - Parte 2/2CES202101 - Clase 9 - Emergencias oncológicas - Parte 2/2
CES202101 - Clase 9 - Emergencias oncológicas - Parte 2/2
 
CES202101 - Clase 8 - Neutropenia febril (Carlos Alberto Betancur Jiménez)
CES202101 - Clase 8 - Neutropenia febril (Carlos Alberto Betancur Jiménez)CES202101 - Clase 8 - Neutropenia febril (Carlos Alberto Betancur Jiménez)
CES202101 - Clase 8 - Neutropenia febril (Carlos Alberto Betancur Jiménez)
 
CES202101 - Clase 7 - Tamización para el cáncer (2/2)
CES202101 - Clase 7 - Tamización para el cáncer (2/2)CES202101 - Clase 7 - Tamización para el cáncer (2/2)
CES202101 - Clase 7 - Tamización para el cáncer (2/2)
 
CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)
CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)
CES202101 - Clase 6 - Tamización contra el cáncer (parte 1/2)
 
CES202101 - Clase 5b - Cáncer de riñón (Daniel González)
CES202101 - Clase 5b - Cáncer de riñón (Daniel González)CES202101 - Clase 5b - Cáncer de riñón (Daniel González)
CES202101 - Clase 5b - Cáncer de riñón (Daniel González)
 

Recently uploaded

Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxdrashraf369
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?bkling
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...saminamagar
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdfDolisha Warbi
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 

Recently uploaded (20)

Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 

TNM8: Changes from TNM7

  • 1. TNM Classification of Malignant Tumours - 8th edition Changes between the 7th and 8th editions “We unite the cancer community to reduce the global cancer burden, to promote greater equity, and to integrate cancer control into the world health and development agenda.” December 2016
  • 2. TNM-8 The TMN 8th edition is being published in December 2016. The UICC TNM Project has published the 8th Edition of the TNM Classification of Malignant Tumours that comes into effect on January 1, 2017. Since some organizations may not be ready to adopt the new classification, we recommend that the edition of the TNM classification be always included in data reporting The following is a summary of the changes between the 7th and 8th editions of TNM. Major changes are listed and minor changes are identified.
  • 3. TNM-8 New classifications: • Oropharynx p16+ve • Unknown primary cervical neck lymph nodes • Skin head and neck cancers • Thymus • Neuroendocrine tumors: pancreas • Osteosarcoma: Pelvic, Spine • Soft tissue Sarcoma: Head and neck, Retroperitoneal, Thoracic and Abdominal Viscera
  • 4. Major modifications • Head and Neck Nodes • Nasopharynx • Thyroid • Esophagus • Stomach • Anal Cancer • Liver • Lung • Prostate • Ovary
  • 5. Minor or no modifications • Introduction • Other Head and Neck carcinomas • Hepatobiliary • Small intestine, Colon and rectum • Neuroendocrine • Pleura • Penis, Kidney, Ureter, Bladder, Urethra, • Eye • Malignant Lymphoma
  • 6. New Structure • Remove C factor from introduction • Clarify ITC • Add Prognostic Grid • Essential TNM • Paediatric Malignancies
  • 7. ITC - UICC • Isolated tumour cells (ITC) are single tumour cells or small clusters of cells not more than 0.2 mm in greatest extent that can be detected by routine H and E stains or immunohistochemistry. An additional criterion has been proposed to include a cluster of fewer than 200 cells in a single histological cross-section others have proposed that a cluster should have 20 cells or fewer; definitions of ITC may vary by tumour site. • The exception is in Malignant Melanoma of the skin and Merkel Cell Carcinoma, wherein ITC in a lymph node are classified as N1. These cases should be analyzed separately.
  • 8. Head and Neck Changes • For all sites there are separate classifications for clinical and pathological neck nodes • There is a new classification for p16 positive oropharyngeal cancers. Tumours that have p16 immunohistochemistry overexpression. • The classification for nasopharyngeal cancers and thyroid cancers has been modified • The there is a new classification for squamous cell carcinoma of the skin in the head and neck region • There is a new classification for cervical nodal involvement with unknown primary
  • 9. Pathological N1, N2a, N2b and N2c unchanged other than specify without extranodal extension • pN3a Metastasis in a lymph node more than 6 cm in greatest dimension without extranodal extension • pN3b Metastasis in a lymph node more than 3 cm in greatest dimension with extranodal extension or, multiple ipsilateral, or any contralateral or bilateral node(s) with extranodal extension Cervical Nodes – 8th edition Clinical N1, N2a, N2b and N2c unchanged other than specify without extranodal extension • N3a Metastasis in a lymph node more than 6 cm in greatest dimension without extranodal extension • N3b Metastasis in a single or multiple lymph nodes with clinical extranodal extension* * The presence of skin involvement or soft tissue invasion with deep fixation/tethering to underlying muscle or adjacent structures or clinical signs of nerve involvement is classified as clinical extra nodal extension
  • 10. Oropharynx p16 Positive tumours Clinical and Pathological T categories • T1 Tumour 2 cm or less in greatest dimension • T2 Tumour more than 2 cm but not more than 4 cm • T3 Tumour more than 4 cm in or extension to lingual surface of epiglottis • T4 Tumour invades any of the following: larynx, deep/ extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), medial pterygoid, hard palate, mandible*, lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, skull base; or encases carotid artery
  • 11. Oropharynx p16 Positive tumours Clinical N categories N0 No regional lymph node metastasis N1 Unilateral metastasis, in lymph node(s), all 6 cm or less N2 Contralateral or bilateral metastasis in lymph node(s), all 6 cm or less in greatest dimension N3 Metastasis in lymph node(s) greater than 6 cm in dimension Pathological N categories pN0 No regional lymph node metastasis pN1 Metastasis in 1 to 4 lymph node(s) pN2 Metastasis in 5 or more lymph node(s)
  • 12. Clinical Stage I T1,T2 N0,1 M0 Stage II T1,T2 N2 M0 T3 N0,N1,N2 M0 Stage III T1-T4 N3 M0 T4 Any N M0 Stage IV Any T Any N M0 Pathological Stage I T1,T2 N0,1 M0 Stage II T1,T2 N2 M0 T3 N0,N1 Stage III T3,T4 N2 M0 Stage IV Any T Any N M0 Oropharynx p16 Positive tumours
  • 13. Nasopharynx T categories T1 Unchanged T2 Tumour with extension to parapharyngeal space and/or infiltration of the medial pterygoid, lateral pterygoid, and/or prevertebral muscles T3 Tumour invades bony structures of skull base cervical vertebra, pterygoid structures, and/or paranasal sinuses T4 Tumour with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, parotid gland and/or infiltration beyond the lateral surface of the lateral pterygoid muscle N Categories N1 Unilateral metastasis, in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyn- geal lymph nodes, 6 cm or less ,above the caudal border of cricoid cartilage N2 Bilateral metastasis in cervical lymph node(s), 6 cm or less above the caudal border of cricoid cartilage N3 Metastasis in cervical lymph node(s) greater than 6 cm in dimension and/or extension below the caudal border of cricoid cartilage
  • 15. Cervical Node Unknown Primary If EBV positive stage as per nasopharyngeal carcinomas If p16 positive stage as per p16 positive oropharynx carcinomas If EBV and p16 negative clinical and pathological node definitions are as above Stage III T0 N1 M0 Stage IVA T0 N2 M0 Stage IVB T0 N3 M0 Stage IVC T0 N1, N2, N3 M1
  • 16. Thyroid Carcinoma Papillary and Follicular The definition of T3 has been revised for papillary and follicular and medullary carcinomas T3a Tumour more than 4 cm in greatest dimension, limited to the thyroid T3b Tumor of any size with gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, or omohyoid muscles) The age for a poor prognosis has changed from 45 years to 55 years Stage < 55 years old Stage I Any T Any N M0 Stage II Any T Any N M1 Stage >55 years old Stage I T1a,T1b,T2 N0 M0 Stage II T3 N0 M0 T1, T2, T3 N1 M0 Stage III T4a Any N M0 Stage IVA T4b Any N M0 Stage IVB Any T Any N M1
  • 17. TNM-8 Oesphagogastric Junction Oesophagus and Gastric Carcinomas • A tumour the epicenter of which is within 2 cm of the oesophagogastric junction and also extends into the oesophagus is classified and staged using the oesophageal scheme. Cancers involving the oesophagogastric junction (OGJ) whose epicenter is within the proximal 2 cm of the cardia (Siewert types I/II) are to be staged as oesophageal • Cancers whose epicenter is more than 2 cm distal from the OGJ will be staged using the Stomach Cancer TNM and Stage even if the OGJ is involved.
  • 18. Oesophagus There are no changes in the definitions of the T, N and M categories. Note there are pathological prognostic groups available for squamous cell carcinoma and clinical and pathological prognostic groups available for adenocarcinoma The AJCC also publish post preoperative therapy prognostic groups for adenocarcinoma and squamous cell carcinoma
  • 19. Oesophagus Squamous Cell Carcinoma Clinical Stage Stage 0 Tis N0 M0 Stage I T1 N0, N1 M0 Stage II T2 N0, N1 M0 T3 N0 M0 Stage III T1,T2 N2 M0 T3 N1, N2 M0 Stage IVA T4a,T4b Any N M0 Stage IVA Any T N3 M0 Stage IVB Any T Any N M1 Pathological Stage Stage 0 Tis N0 M0 Stage IA T1a N0 M0 Stage IB T1b N0 M0 T2 N0 M0 Stage II T3 N0 M0 T1 N1 M0 Stage IIIA T1 N2 M0 T2 N1 M0 Stage IIIB T2 N2 M0 T3 N1, N2 M0 T4a N0, N1 M0 Stage IVA T4a N2 M0 T4b Any N M0 Any T N3 M0 Stage IVB Any T Any N M1
  • 20. Oesophagus Adenocarcinoma Clinical Stage Stage 0 Tis N0 M0 Stage I T1 N0 M0 Stage IIA T1 N1 M0 IIB T2 N0 M0 Stage III T1 N2 M0 T2 N1, N2 M0 T3,T4a N0, N1, M0 Stage IVA T4b N0, N1 M0 Any T N2, N3 M0 Stage IVB Any T Any N M1 Pathological Stage Stage 0 Tis N0 M0 Stage IA T1a N0 M0 Stage IB T1b N0 M0 Stage IIA T2 N0 M0 Stage IIB T1a,T1b N1 M0 Stage IIIA T1 N2 M0 T2 N1 M0 T3, T4a N0 M0 Stage IIIB T2 N2 M0 T3 N1, N2 M0 T4a N1 M0 Stage IVA T4a N2 M0 T4b Any N M0 Any T N3 M0 Stage IVB Any T Any N M1
  • 21. Gastric Carcinoma Adenocarcinoma Clinical Stage Stage I T1, T2, N0 M0 Stage IIA T1, T2, N1, N2, N3 M0 Stage IIB T3, T4a N0 M0 Stage III T3, T4a N1, N2, N3 M0 Stage IV T4b Any N M0 Stage IV Any T Any N M1 Pathological Stage Stage 0 Tis N0 M0 Stage IA T1 N0 M0 Stage IB T1 N1 M0 T2 N0 M0 Stage IIA T1 N2 M0 T2 N1 M0 T3 N0 M0 Stage IIB T1 N3a M0 T2 N2 M0 T3 N1 M0 T4a N0 M0
  • 22. Colon and Rectum Definition of tumour deposit clarified Tumour deposits (satellites) are discrete macroscopic or microscopic nodules of cancer in the pericolorectal adipose tissue’s lymph drainage area of a primary carcinoma that are discontinuous from the primary and without histological evidence of residual lymph node or identifiable vascular or neural structures. If a vessel wall is identifiable on H&E, elastic or other stains, it should be classified as venous invasion (V1/2) or lymphatic invasion (L1). Similarly, if neural structures are identifiable, the lesion should be classified as perineural invasion (Pn1). The presence of tumour deposits does not change the primary tumour T category, but changes the node status (N) to N1c if all regional lymph nodes are negative on pathological examination
  • 23. Colon and Rectum and Appendix T and N categories Unchanged M1 Distant metastasis M1a Metastasis confined to one organ (liver, lung, ovary, non regional lymph node(s)) without peritoneal metastases M1b Metastasis in more than one organ M1c Metastasis to the peritoneum with or without other organ involvement Stage Unchanged except for Stage IVA, IVB, IVC as below Stage IV Any T Any N M1 Stage IVA Any T Any N M1a Stage IVB Any T Any N M1b Stage IVC Any T Any N M1c Appendix Introduction of Tis (LAMN). Low-grade appendiceal mucinous neoplasm confined to the appendix Changes to N and M categories and Stage
  • 24. Anal Canal Carcinoma Tumours of anal margin and perianal skin defined as within 5cm of the anal margin are now classified with carcinomas of the anal canal T categories are unchanged N0 No regional lymph node metastasis N1 Metastasis in regional lymph node(s) N1a Metastases in inguinal, mesorectal, and/or internal iliac nodes N1b Metastases in external iliac nodes N1c Metastases in external iliac and in inguinal, mesorectal and/or internal iliac nodes M categories are unchanged Stage Stage I T1 N0 M0 Stage IIA T2 N0 M0 Stage IIB T3 N0 M0 Stage IIIA T1, T2 N1 M0 Stage IIIB T4 N0 M0 Stage IIIC T3, T4 N1 M0 Stage IV Any T Any N M1
  • 25. Liver T1a Solitary tumour less than or equal to 2 cm in greatest dimension with or without vascular invasion T1b Solitary tumor more than 2 cm in greatest dimension without vascular invasion T2 Solitary tumour with vascular invasion more than 2 cm dimension or multiple tumours, none more than 5 cm in greatest dimension T3 Multiple tumours any more than 5 cm in greatest dimension T4 Tumour(s) involving a major branch of the portal or hepatic vein with direct invasion of adjacent organs including the diaphragm), other than the gallbladder or with perforation of visceral peritoneum There are no changes in the definitions of the N and M categories. Stage Stage I A T1a N0 M0 Stage I B T1b N0 M0 Stage II T2 N0 M0 Stage IIIA T3 N0 M0 Stage IIIB T4 N0 M0 Stage IVA Any T N1 M0 Stage IVB Any T Any N M1
  • 26. Intrahepatic Bile Ducts • Changes in definitions of T1 and T2 categories • Changes in Stage Gall Bladder • Changes in definitions of T2 category and N categories • Change in Stage Perihilar Bile Ducts No Changes Distal Extrahepatic Bile Duct • Changes in definitions of T1,T2,T3 categories and N categories • Changes in Stage Ampulla of Vater • Changes in definitions of T1,T2 and T3 categories and N categories • Changes in Stage Well differentiated Neuroendocrine Tumours of the Gastrointestinal Tract • Pancreas added • Minor changes in T categories. • Changes in N category for Jejunum and Ileum • Minor changes in Stage
  • 27. Pancreas T1 Tumour 2 cm or less T1a Tumour 0.5 cm or less T1b Tumour greater than 0.5 cm and less than 1 cm T1c Tumor greater than 1 cm but no more than 2 cm T2 Tumour more than 2 cm but no more than 4 cm T3 Tumour more than 4 cm in greatest dimension T4 Tumour involves coeliac axis, superior mesenteric artery and/or common hepatic artery N1 Metastases in 1 to 3 nodes N2 Metastases in 4 or more nodes M category unchanged Stage Stage IA T1 N0 M0 Stage IB T2 N0 M0 Stage IIA T3 N0 M0 Stage IIB T1, T2, T3 N1 M0 Stage III T1, T2, T3 N2 M0 T4 Any N M0 Stage IV Any T Any N M1
  • 28. Lung T1 Tumour 3 cm or less T1mi Minimally invasive adenocarcinoma T1a Tumour 1 cm or less T1b Tumour more than 1 cm but not more than 2 cm T1c Tumour more than 2 cm but not more than 3 cm T2 Tumour more than 3 cm but not more than 5 cm; or tumour with any of the following features: Involves main bronchus without involvement of the carina, or invades visceral pleura or associated with atelectasis or obstructive pneumonitis T2a Tumour more than 3 cm but not more than 4 cm T2b Tumour more than 4 cm but not more than 5 cm
  • 29. Lung T3 Tumour more than 5 cm but not more than 7 cm or directly invades: parietal pleura, chest wall, phrenic nerve, or parietal pericardium; or separate tumour nodule(s) in the same lobe. T4 Tumour more than 7 cm or of any size that invades any of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina; or separate tumour nodule(s) in a different ipsilateral lobe to the primary N Category- No Change M Category M1a Separate tumour nodule(s) in a contralateral lobe; tumour with pleural or pericardial nodules or malignant pleural or pericardial effusion M1b Single extrathoracic metastasis in a single organ M1c Multiple extrathoracic metastasis in a single or multiple organs
  • 30. Lung Stage IA T1 N0 M0 Stage IA1 T1mi,T1a N0 M0 Stage IA2 T1b N0 M0 Stage IA3 T1c N0 M0 Stage IB T2a N0 M0 Stage IIA T2b N0 M0 Stage IIB T1a-c, T2a,b N1 M0 T3 N0 M0 Stage IIIA T1a-c, T2a,b N2 M0 T3 N1 T4 N0,N1 M0 Stage IIIB T1a-c, T2a,b N3 M0 T3, T4 N2 M0 Stage IIIC T3, T4 N3 M0 Stage IV Any T Any N M1 Stage IVA Any T Any N M1a,b Stage IVB Any T Any N M1c
  • 31. Mesothelioma and Thymus Mesothelioma Minor change in T1 category Changes in N category Changes in Stage Thymus Please see details in Nicholson AG, Detterbeck FC, Marino M et al. The IASLC/ITMIG thymic epithelial tumors staging project: proposals for the T component for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014; 9: s73- s80.
  • 32. Bone and Soft Tissues Sarcoma Bone • No Changes for sarcomas of the Appendicular Skeleton, Trunk, Skull and Facial Bones • New Classifications introduced for Spine and Pelvic Bone Sarcomas Soft Tissues sarcoma New T categories for Extremity and Superficial Trunk T1 Tumour 5 cm or less T2 Tumour more than 5 cm but no more than 10 cm T3 Tumour more than 10 cm but no more than 15 cm T4 Tumour more than 15 cm New Classification for retroperitoneal sarcoma (same as extremity) Head and Neck and also Thoracic and Abdominal Viscera
  • 33. Skin carcinomas T categories T1 < 2 cm T2 > 2 to 4cm T3 > 4 cm T4a Tumor with gross cortical bone / marrow invasion T4b Tumor with skull base or axial skeleton invasion including foraminal involvement and/or vertebral foramen involvement to the epidural space N Categories for non head and neck N1 Metastasis in a single lymph node 3 cm or less N2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm or in multiple ipsilateral nodes none more than 6 cm N3 Metastasis in a lymph node more than 6 cm Head and Neck Region N categories as defined in slide 9
  • 34. Skin carcinomas Stage Stage I T1 N0 M0 Stage II T2 N0 M0 Stage III T3 N0 M0 T1, T2, T3 N1 M0 Stage IVA T1, T2, T3 N2, N3 M0 T4 Any N M0 Stage IVB Any T Any N M1
  • 35. Malignant Melanoma & Merkel cell carcinoma Cutaneous Melanoma • pT1a and pT1b categories introduced • pT1a < 0.8mm • pT1b > 0.8mm -1mm • M category • M1a Skin, subcutaneous tissue or non regional lymph nodes • M1b Lung • M1c Other non-central nervous system sites • M1d Central nervous system • M Category modified by elevated or non-elevated LDH Stage Revised Merkel cell • Changes in cN and pN classification and in Stage
  • 36. Genitourinary Malignancies and Adrenal Cortex Prostate T4N0M0 is now stage III WHO Grade should be used to record tumour grade Stage Stage I T1, T2a N0 M0 Stage II T2b-2c N0 M0 Stage III T3,T4 N0 M0 Stage IV Any T N1 M0 Any T Any N M1 Penis Changes in T category and pathological N category Kidney N2 is eliminated
  • 37. Genitourinary Malignancies and Adrenal Cortex Urinary bladder The M category is subdivided M1a Non regional lymph nodes M1b Other distant metastasis Minor changes to Stage Urethra Changes to N category N1 Metastasis in a single lymph node N2 Metastasis in multiple lymph nodes Adrenal Cortex Change in Stage Stage I T1 N0 M0 Stage II T2 N0 M0 Stage III T1, T2 N1 M0 T3, T4 N0, N1 M0 Stage IV Any T Any N M1
  • 38. Ovary – 8th ed TNM and Ovary, Fallopian Tube and Primary Peritoneal Carcinoma based on FIGO 2014 FIGO has published a new classification for ovarian cancer* This classification incorporates cancers of the fallopian tube and primary peritoneal carcinomas Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Jaime Prat; for the FIGO Committee on Gynecologic Oncology. International Journal of Gynecology and Obstetrics 124 (2014) 1–5
  • 39. Ovary, Fallopian Tube and Primary Peritoneum T1 Limited to the ovaries I Tla One ovary, (capsule intact) IA or fallopian tube Tlb Both ovaries, capsule intact IB TIc1 Surgical Spill IC1 TIc2 Capsule ruptured before surgery or IC2 tumour on surface of ovary or tube TIc3 Malignant cells in ascites or IC3 peritoneal washings T2 Pelvic extension below pelvic brim or primary peritoneal cancer II T2a Uterus, tube(s), ovary (ies) IIA T2b Other pelvic tissues IIB T3 and/or Peritoneal metastasis beyond pelvis N1 and/or regional lymph node metastasis III T1/T2 N1 Retroperitonal nodes only IIIA1 T1/T2 N1a < 10mm IIIA1i T1/T2 N1b > 10mm IIIA1ii T3a N0/N1 Microscopic peritoneal metastasis T3b N0/N1 Macroscopic peritoneal metastasis < 2cm IIIB T3c N0/N1 Peritoneal metastasis >2 cm IIIC M1 Distant metastasis (excludes peritoneal) IV M1a Pleural effusion positive cytology IVB M1b Parenchymal metastases IVB
  • 40. Malignant Lymphoma A recent consensus conference in Lugano suggested a more simplified system putting together stage I and II as Limited Stage and stage III and IV as Advanced Stage lymphoma. Limited Stage • Stage I • Stage II • Bulky Stage II Advanced Stage • Stage III • Stage IV Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32: 3059-3068
  • 41. Ophthalmic Tumours Carcinoma of Conjunctiva • Minor changes to definition of T1 and T2 categories Malignant Melanoma of Conjunctiva • Changes to the pathological T categories Malignant Melanoma of Uvea • Iris • Minor changes to definition T2 category Retinoblastoma • Changes to definition of cT1 and cM categories and pT and pM categories Sarcoma of the Orbit • Minor changes to definition of T1 and T2 categories Carcinoma of Lacrimal Gland • Changes to the T categories
  • 42. Essential TNM Information on anatomical extent of disease at presentation is often not available for cancer registries in low and middle in-come countries either because of inability to perform necessary investigations or because of lack of recording of information. The UICC TNM Project has with the International Agency for Research in Cancer and the National Cancer Institute developed “Essential TNM” that can be used to collect stage data when complete information is not available. When the T, N, and M categories have not been the cancer registrar can code the extent of disease according to the Essential TNM scheme. The schema for breast, colorectal cancer, prostate and cervix cancer published in the 8th edition TNM Classification and are available on the website.
  • 43. Paediatric Tumours A consensus meeting held in 2014 recommended a tiered staging system with more detailed systems for well-resourced cancer registries and less detailed systems for registries with limited recourses and access The recommendations for tier 1 and 2 follow are published the the 8th edition TNM Classification of Malignant Tumours. For some cancers recommendations are the same as described earlier for adult patients.
  • 44. UNION FOR INTERNATIONAL CANCER CONTROL UNION INTERNATIONALE CONTRE LE CANCER 62 route de Frontenex, 1207 Geneva, Switzerland T. +41 (0)22 809 1811 F. +41 (0)22 809 1810 www.uicc.org Thank you